Drug intelligence / Profile preview

lithium + ziprasidone

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of lithium (a mood stabilizer) and ziprasidone (an atypical antipsychotic). This combination is primarily used for the maintenance treatment of bipolar disorder, particularly for patients who continue to experience inadequate control of manic or mixed symptomatology with lithium monotherapy. Ziprasidone works as a dopamine D2 and serotonin 5HT2A antagonist with serotonin reuptake inhibition properties, while lithium acts as a mood stabilizer. The combination was approved by the FDA in 2009 for maintenance treatment in bipolar disorder.

Targets

DRD4 (Dopamine D4 Receptor)HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)HRH1 (Histamine H1 Receptor)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on lithium + ziprasidone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lithium + ziprasidone.

Explore the full profile